GLUE logo

Monte Rosa Therapeutics (GLUE)

Profile

Full Name

Monte Rosa Therapeutics, Inc.

Ticker Symbol

GLUE

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

June 24, 2021

Indexes

Not included

Website

http://www.monterosatx.com

Employees

134

Key Details

Price

$4.22(+1.69%)

Market cap

$259.57M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$75.62M

Annual EPS

-$0.98(+62.74% YoY)

PE ratio

-

Next earnings date

May 9, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$4.22
GLUE price is $4.22

30-Day Relative Volume

0.78
GLUE 30-day relative volume is 0.78

Price Performance

Price Today change

+1.69%
GLUE price is up +1.69% today

Price YTD change

-39.19%
GLUE price is down -39.19% since January 1st

Price 1-year change

-41.14%
GLUE price is down -41.14% year-on-year

Price 3-year change

-66.85%
GLUE price is down -66.85% over the past 3 years

Price Range

Price All-time high

$45.56
GLUE price is currently -90.74% below its historical high of $45.56

Price 3-year low

$2.44
GLUE price is currently +72.95% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$259.57M
GLUE market capitalization is $259.57 million

Market cap 3-year change

-56.27%
GLUE market capitalization is down -56.27% over the past 3 years

Market cap All-time high

$1.96B
GLUE market capitalization is currently -86.74% below its historical high of $1.96 billion

Market cap sector rank

61.54%
GLUE market capitalization is higher than 61.54% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+22.53%
GLUE shares outstanding is up +22.53% year-on-year

Shares Outstanding 3-Year Change

+31.91%
GLUE shares outstanding is up +31.91% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.30
GLUE beta is 1.30

200-day SMA

$6.10
GLUE price is currently -30.77% below its 200-day simple moving average

50-day SMA

$5.81
GLUE price is currently -27.36% below its 50-day simple moving average

RSI

34.48
GLUE 14-day relative strength index is 34.48

Volume

0.78
GLUE 30-day relative volume is 0.78

ATR

$0.46
GLUE average true range is $0.46

10-day Historical Volatility

83.96%
GLUE 10-day historical volatility is 83.96%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$75.62M
GLUE annual revenue is $75.62 million

Revenue Analysts estimate

$53.54M
GLUE annual revenue is currently +41.25% higher than the consensus analysts' forecast

Revenue 1-year change

-
GLUE annual revenue 1-year change is unknown

Revenue Sector rank

52.52%
GLUE annual revenue is higher than 52.52% of companies in Healthcare sector

EPS

EPS

-$0.98
GLUE annual earnings per share is -$0.98

EPS Analysts estimate

-$1.54
GLUE annual earnings per share is currently -36.24% lower than the consensus analysts' forecast

EPS 1-year change

+62.74%
GLUE annual earnings per share is up +62.74% year-on-year

EPS Sector rank

57.31%
GLUE annual earnings per share is higher than 57.31% of companies in Healthcare sector

Profit

Gross profit

-
GLUE annual gross profit value is unknown

Gross margin

-
GLUE annual gross profit margin value is unknown

Operating profit

-$81.11M
GLUE annual operating income is -$81.11 million

Operating margin

-107.26%
GLUE annual operating profit margin is -107.26%

Net income

-$72.70M
GLUE annual net profit is -$72.70 million

Net margin

-96.14%
GLUE annual net profit margin is -96.14%

Expenses

Total expenses

$156.73M
GLUE annual total expenses is $156.73 million

Operating expenses

$156.73M
GLUE annual total operating expenses is $156.73 million

Cost of goods sold

-
GLUE annual cost of goods sold value is unknown

Selling, general & administrative expenses

$35.17M
GLUE annual SGA is $35.17 million

Depreciation and amortization

$8.12M
GLUE annual depreciation & amortization is $8.12 million

Interest expense

-
GLUE annual interest expense value is unknown

Income tax

$2.57M
GLUE annual income tax is $2.57 million

EBIT & EBITDA

EBIT

-$81.11M
GLUE annual earnings before interest & taxes is -$81.11 million

EBITDA

-$72.99M
GLUE annual EBITDA is -$72.99 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$438.73M
GLUE annual total assets is $438.73 million

Non current assets

$61.29M
GLUE annual long term assets is $61.29 million

Current assets

$377.44M
GLUE annual total current assets is $377.44 million

Cash and cash equivalents

$224.25M
GLUE annual cash & cash equivalents is $224.25 million

Accounts receivable

-
GLUE annual accounts receivable value is unknown

Inventory

-
GLUE annual inventory value is unknown

Liabilities

Total liabilities

$215.80M
GLUE annual total liabilities is $215.80 million

Long term liabilities

$58.85M
GLUE annual total long term liabilities is $58.85 million

Current liabilities

$156.95M
GLUE annual total current liabilities is $156.95 million

Accounts payable

$17.21M
GLUE annual accounts payable is $17.21 million

Debt

Total debt

$42.72M
GLUE annual total debt is $42.72 million

Total debt 1-year change

-7.22%
GLUE annual total debt is down -7.22% year-on-year

Long term debt

$39.00M
GLUE annual long term debt is $39.00 million

Short term debt

$3.71M
GLUE annual short term debt is $3.71 million

Equity & Capital

Shareholders equity

$222.94M
GLUE annual stockholders equity is $222.94 million

Book value

$222.94M
GLUE annual book value is $222.94 million

Retained earnings

-$438.59M
GLUE annual retained earnings is -$438.59 million

Working capital

$220.49M
GLUE annual working capital is $220.49 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

$42.00M
GLUE annual cash flow from operations is $42.00 million

Cash from operations 1-year change

+195.88%
GLUE annual cash flow from operations is up +195.88% year-on-year

Cash from investing

-$44.45M
GLUE annual cash flow from investing activities is -$44.45 million

Cash from investing 1-year change

-150.06%
GLUE annual cash flow from investing activities is down -150.06% year-on-year

Cash from financing

$98.89M
GLUE annual cash flow from financing activities is $98.89 million

Cash from financing 1-year change

+259.71%
GLUE annual cash flow from financing activities is up +259.71% year-on-year

CAPEX

CAPEX

$3.99M
GLUE annual capital expenditures is $3.99 million

CAPEX 1-year change

-
GLUE annual capital expenditures 1-year change is unknown

Free Cash Flow

Free cash flow

$38.01M
GLUE annual free cash flow is $38.01 million

Free cash flow 1-year change

+160.48%
GLUE annual free cash flow is up +160.48% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
GLUE annual gross profit margin value is unknown

Operating margin

-107.26%
GLUE annual operating profit margin is -107.26%

Net margin

-96.14%
GLUE annual net profit margin is -96.14%

ROA & ROE

ROA

-16.57%
GLUE annual return on assets is -16.57%

ROE

-36.15%
GLUE annual return on equity is -36.15%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
GLUE price to earnings ratio value is unknown

PE ratio Sector rank

-
GLUE price to earnings ratio is unknown

PB Ratio

PB ratio

1.16
GLUE price to book ratio is 1.16

PB ratio Sector rank

48.11%
GLUE price to book ratio is higher than 48.11% of companies in Healthcare sector

PS Ratio

PS ratio

3.43
GLUE price to sales ratio is 3.43

PS ratio Sector rank

57.44%
GLUE price to sales ratio is higher than 57.44% of companies in Healthcare sector

Enterprise value

Enterprise value

$78.03M
GLUE enterprise value is $78.03 million

Enterprise value Sector rank

47.24%
GLUE enterprise value is higher than 47.24% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-1.07
GLUE EV/EBITDA is -1.07

EV/EBITDA Sector rank

41.06%
GLUE EV/EBITDA is higher than 41.06% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

2.40
GLUE annual current ratio is 2.40

Quick ratio

-
GLUE annual quick ratio value is unknown

Leverage

Debt to equity

0.00
GLUE annual debt to equity ratio is 0.00

Interest coverage ratio

-
GLUE annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
GLUE piotroski f-score value is unknown

Altman Z-Score

-0.51
GLUE altman z-score is -0.51

Analyst ratings

Recent major analysts updates

Mar 21, 25 Wells Fargo
Equal-Weight
Mar 21, 25 Wedbush
Outperform
Mar 12, 25 LifeSci Capital
Outperform
Dec 19, 24 Wells Fargo
Equal-Weight
Sep 12, 24 Wedbush
Outperform
Aug 12, 24 Wells Fargo
Overweight
Jun 28, 24 Piper Sandler
Overweight
May 22, 24 Wedbush
Outperform
Feb 15, 24 Wedbush
Outperform
Oct 19, 23 JP Morgan
Overweight

Institutional Ownership

Similar stocks

DCGO logo
DocGo (DCGO)
MRVI logo
Maravai LifeSciences Holdings (MRVI)
NRC logo
National Research (NRC)
SMTI logo
Sanara MedTech (SMTI)
ARCT logo
Arcturus Therapeutics Holdings (ARCT)
VMD logo
Viemed Healthcare (VMD)
ZIMV logo
ZimVie (ZIMV)
TSVT logo
2seventy bio (TSVT)
CMPS logo
COMPASS Pathways (CMPS)
  • What is the ticker symbol for Monte Rosa Therapeutics?
  • Does Monte Rosa Therapeutics pay dividends?
  • What sector is Monte Rosa Therapeutics in?
  • What industry is Monte Rosa Therapeutics in?
  • What country is Monte Rosa Therapeutics based in?
  • When did Monte Rosa Therapeutics go public?
  • Is Monte Rosa Therapeutics in the S&P 500?
  • Is Monte Rosa Therapeutics in the NASDAQ 100?
  • Is Monte Rosa Therapeutics in the Dow Jones?
  • When was Monte Rosa Therapeutics's last earnings report?
  • When does Monte Rosa Therapeutics report earnings?
  • Should I buy Monte Rosa Therapeutics stock now?

What is the ticker symbol for Monte Rosa Therapeutics?

The ticker symbol for Monte Rosa Therapeutics is NASDAQ:GLUE

Does Monte Rosa Therapeutics pay dividends?

No, Monte Rosa Therapeutics does not pay dividends

What sector is Monte Rosa Therapeutics in?

Monte Rosa Therapeutics is in the Healthcare sector

What industry is Monte Rosa Therapeutics in?

Monte Rosa Therapeutics is in the Biotechnology industry

What country is Monte Rosa Therapeutics based in?

Monte Rosa Therapeutics is headquartered in United States

When did Monte Rosa Therapeutics go public?

Monte Rosa Therapeutics's initial public offering (IPO) was on June 24, 2021

Is Monte Rosa Therapeutics in the S&P 500?

No, Monte Rosa Therapeutics is not included in the S&P 500 index

Is Monte Rosa Therapeutics in the NASDAQ 100?

No, Monte Rosa Therapeutics is not included in the NASDAQ 100 index

Is Monte Rosa Therapeutics in the Dow Jones?

No, Monte Rosa Therapeutics is not included in the Dow Jones index

When was Monte Rosa Therapeutics's last earnings report?

Monte Rosa Therapeutics's most recent earnings report was on Mar 20, 2025

When does Monte Rosa Therapeutics report earnings?

The next expected earnings date for Monte Rosa Therapeutics is May 9, 2025

Should I buy Monte Rosa Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page